220 related articles for article (PubMed ID: 30504201)
1. Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
Sánchez LM; Nieves RM; Latham T; Stuber S; Luden JR; Urcuyo GS; Berges ME; Florencio C; Gonzalez C; Del Villar P; Lane A; Schultz W; Jeste N; Mena R; Ware RE
Blood Adv; 2018 Nov; 2(Suppl 1):50-53. PubMed ID: 30504201
[No Abstract] [Full Text] [Related]
2. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
[No Abstract] [Full Text] [Related]
3. Expanding the role of hydroxyurea in children with sickle cell disease.
Rogers ZR; Buchanan GR
J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
[No Abstract] [Full Text] [Related]
4. Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.
DeBaun MR
J Pediatr; 2005 Oct; 147(4):560-1. PubMed ID: 16227052
[No Abstract] [Full Text] [Related]
5. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
[TBL] [Abstract][Full Text] [Related]
6. What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
Estepp JH; Cong Z; Agodoa I; Kang G; Ding J; McCarville MB; Hankins JS; Wang WC
Br J Haematol; 2021 Jul; 194(2):463-468. PubMed ID: 34131902
[TBL] [Abstract][Full Text] [Related]
7. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Rankine-Mullings A; Reid M; Soares D; Taylor-Bryan C; Wisdom-Phipps M; Aldred K; Latham T; Schultz WH; Knight-Madden J; Badaloo A; Lane A; Adams RJ; Ware RE
Br J Haematol; 2021 Nov; 195(4):612-620. PubMed ID: 34291449
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis.
Suliman H; Wali Y; Al Saadoon M; Zechariah M; William RR; Gujjar A; Pathare A
J Pediatr Hematol Oncol; 2009 Jan; 31(1):42-4. PubMed ID: 19125086
[TBL] [Abstract][Full Text] [Related]
9. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
[TBL] [Abstract][Full Text] [Related]
10. Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
Lefèvre N; Dufour D; Gulbis B; Lê PQ; Heijmans C; Ferster A
Blood; 2008 Jan; 111(2):963-4; author reply 964. PubMed ID: 18182580
[No Abstract] [Full Text] [Related]
11. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease.
Mack AK; Thompson AA
J Pediatr Health Care; 2017; 31(2):145-154. PubMed ID: 27423528
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
Cunningham-Myrie C; Abdulkadri A; Waugh A; Bortolusso Ali S; King LG; Knight-Madden J; Reid M
Pediatr Blood Cancer; 2015 Oct; 62(10):1862-4. PubMed ID: 25929458
[TBL] [Abstract][Full Text] [Related]
13. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea and stroke prevention in sickle cell anaemia: the challenge of application in sub-Saharan Africa.
Diop S; de Montalembert M
Lancet Haematol; 2023 Apr; 10(4):e237-e238. PubMed ID: 36870359
[No Abstract] [Full Text] [Related]
15. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea for ALL children with sickle cell anemia: What can we learn from Africa?
Aygun B
Pediatr Blood Cancer; 2020 Apr; 67(4):e28164. PubMed ID: 31925887
[No Abstract] [Full Text] [Related]
17. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
[No Abstract] [Full Text] [Related]
18. Stroke in patients with sickle cell disease.
Webb J; Kwiatkowski JL
Expert Rev Hematol; 2013 Jun; 6(3):301-16. PubMed ID: 23782084
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
[TBL] [Abstract][Full Text] [Related]
20. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
DeBaun MR
Blood; 2020 May; 135(22):1997-1999. PubMed ID: 32282033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
